PROFUND ADVISORS LLC

Position in PTGX — Protagonist Therapeutics, Inc

CIK 1129919 BETHESDA, MD

Position in PTGX

as of Mar 31, 2026 · filed Apr 27, 2026 Compact

Position Value

$2,410,181

+$176,548 QoQ

Shares Held

22,867

-10.6% QoQ

Ownership

0.036%

of shares outstanding

% of Portfolio

0.09%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2023

13 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

PROFUND ADVISORS LLC holds $170,243,760 across 158 Biotechnology names. PTGX ranks #8 (1.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	23,137	$10,331,595
2	REGN	Regeneron Pharmaceuticals, Inc.	10,332	$7,982,916
3	ALNY	Alnylam Pharmaceuticals, Inc.	14,647	$4,846,252
4	INSM	INSMED Inc	27,937	$4,568,258
5	MDGL	Madrigal Pharmaceuticals, Inc.	4,862	$2,545,111
6	TGTX	Tg Therapeutics, Inc.	76,039	$2,526,015
7	ARWR	Arrowhead Pharmaceuticals, Inc.	39,758	$2,492,826
8	PTGX	Protagonist Therapeutics, Inc This page	22,867	$2,410,181

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$2,410,181	22,867	-10.6%	Shares	Sole	2026-04-27
2025-12-31	$2,233,633	25,574	+40.8%	Shares	Sole	2026-02-06
2025-09-30	$1,206,169	18,157	-4.8%	Shares	Sole	2025-11-06
2025-06-30	$1,054,219	19,074	+65.0%	Shares	Sole	2025-08-07
2025-03-31	$558,993	11,559	-44.0%	Shares	Sole	2025-05-08
2024-12-31	$797,051	20,649	+2.8%	Shares	Sole	2025-02-14
2024-09-30	$903,735	20,083	+38.2%	Shares	Sole	2024-11-14
2024-06-30	$503,429	14,529	-61.2%	Shares	Sole	2024-08-13
2024-03-31	$1,084,151	37,475	+34.4%	Shares	Sole	2024-05-08
2023-12-31	$639,517	27,890	-52.5%	Shares	Sole	2024-02-14
2023-09-30	$979,382	58,716	+13.4%	Shares	Sole	2023-11-13
2023-06-30	$1,430,246	51,783	+79.8%	Shares	Sole	2023-08-10
2023-03-31	$662,400	28,800	—	Shares	Sole	2023-05-12
No filing history on record for this holder in this stock.